Supernus Pharmaceuticals Inc Valuation – Initial Coverage $SUPN
Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Stocks for Using A Benjamin Graham Value Investing Strategy – February 2017. By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Supernus Pharmaceuticals Inc (SUPN) fares in the ModernGraham valuation model.
Company Profile (obtained from Google Finance): Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
[level-free]
To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.
Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Recent valuations of the components of the Dow Jones Industrial Average are available for free members, including this one of Microsoft Corporation.  In addition, here is a post detailing what can be found within each individual company’s valuation.
[otw_shortcode_button href=”https://www.moderngraham.com/moderngraham-stocks-screens/” size=”medium” icon_position=”left” shape=”square”]Learn More About Premium Membership[/otw_shortcode_button]
[/level-free]
[not-level-free]
Downloadable PDF version of this valuation:
ModernGraham Valuation of SUPN – March 2017
Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?
What kind of Intelligent Investor are you?
| Defensive Investor; must pass 6 out of the following 7 tests. | ||||
| 1. Adequate Size of the Enterprise | Market Cap > $2Bil | $1,410,716,915 | Fail | |
| 2. Sufficiently Strong Financial Condition | Current Ratio > 2 | 1.88 | Fail | |
| 3. Earnings Stability | Positive EPS for 10 years prior | Fail | ||
| 4. Dividend Record | Dividend Payments for 10 years prior | Fail | ||
| 5. Earnings Growth | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | -111.33% | Fail | |
| 6. Moderate PEmg Ratio | PEmg < 20 | 44.30 | Fail | |
| 7. Moderate Price to Assets | PB Ratio < 2.5 OR PB*PEmg < 50 | 7.38 | Fail | |
| Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor. | ||||
| 1. Sufficiently Strong Financial Condition | Current Ratio > 1.5 | 1.88 | Pass | |
| 2. Sufficiently Strong Financial Condition | Debt to NCA < 1.1 | 0.06 | Pass | |
| 3. Earnings Stability | Positive EPS for 5 years prior | Fail | ||
| 4. Dividend Record | Currently Pays Dividend | Fail | ||
| 5. Earnings Growth | EPSmg greater than 5 years ago | Fail | ||
Stage 2: Determination of Intrinsic Value
| EPSmg | $0.61 |
| MG Growth Estimate | -4.25% |
| MG Value | $0.65 |
| Opinion | Overvalued |
| MG Grade | F |
| MG Value based on 3% Growth | $8.90 |
| MG Value based on 0% Growth | $5.22 |
| Market Implied Growth Rate | 17.90% |
| Current Price | $27.20 |
| % of Intrinsic Value | 4212.35% |
Supernus Pharmaceuticals Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the small size, low current ratio, insufficient earnings stability or growth over the last ten years, the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor has concerns regarding the lack of earnings stability or growth over the last five years, and the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.
As for a valuation, the company appears to be Overvalued after seeing its EPSmg (normalized earnings) decline from $1.07 in 2013 to an estimated $0.61 for 2017. This level of demonstrated earnings growth does not support the market’s implied estimate of 17.9% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.
At the time of valuation, further research into Supernus Pharmaceuticals Inc revealed the company was trading above its Graham Number of $8.88. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 43.89, which was above the industry average of 28.95. Finally, the company was trading above its Net Current Asset Value (NCAV) of $0.65.
Supernus Pharmaceuticals Inc scores quite poorly in the ModernGraham grading system, with an overall grade of F.
Stage 3: Information for Further Research
| Net Current Asset Value (NCAV) | $0.65 |
| Graham Number | $8.88 |
| PEmg | 43.89 |
| Current Ratio | 1.88 |
| PB Ratio | 7.31 |
| Current Dividend | $0.00 |
| Dividend Yield | 0.00% |
| Number of Consecutive Years of Dividend Growth | 0 |
[/not-level-free]
Useful Links:
| ModernGraham tagged articles | Morningstar |
| Google Finance | MSN Money |
| Yahoo Finance | Seeking Alpha |
| GuruFocus | SEC Filings |
Most Recent Balance Sheet Figures
| Balance Sheet Information | 12/1/2016 |
| Total Current Assets | $151,404,000 |
| Total Current Liabilities | $80,742,000 |
| Long-Term Debt | $4,165,000 |
| Total Assets | $309,568,000 |
| Intangible Assets | $16,490,000 |
| Total Liabilities | $117,813,000 |
| Shares Outstanding (Diluted Average) | 52,021,000 |
Earnings Per Share History
| EPS History | |
| Next Fiscal Year Estimate | $0.95 |
| Dec2016 | $1.76 |
| Dec2015 | $0.28 |
| Dec2014 | -$0.26 |
| Dec2013 | -$2.90 |
| Dec2012 | -$2.72 |
| Dec2011 | $31.39 |
| Dec2010 | -$26.38 |
Earnings Per Share – ModernGraham History
| EPSmg History | |
| Next Fiscal Year Estimate | $0.61 |
| Dec2016 | $0.04 |
| Dec2015 | $1.17 |
| Dec2014 | $1.02 |
| Dec2013 | $1.07 |
| Dec2012 | $2.19 |
| Dec2011 | $3.43 |
| Dec2010 | -$8.79 |
Recommended Reading:
Other ModernGraham posts about the company
None. This is the first time ModernGraham has covered the company.
Other ModernGraham posts about related companies
Disclaimer:
The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.
